| Julie Boyd Damp, MD | |
|
1215 21st Ave S, Mce 5th Floor South Tower, Nashville, TN 37232-0014 | |
| (615) 322-2318 | |
| Not Available |
| Full Name | Julie Boyd Damp |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 23 Years |
| Location | 1215 21st Ave S, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144377011 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0000039059 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Tennova Healthcare-shelbyville | Shelbyville, TN | Hospital |
| Tennova Healthcare-harton | Tullahoma, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
Clinical Foundations, a patient-focused education program dedicated to helping respiratory care professionals stay current on clinical trends, has recently published a new edition titled "Pathogens Associated with the Intensive Care Unit Environment –Considerations for the Respiratory Therapist."
Gambling activity is widespread among U.S. adolescents and young adults ages 14 through 21, according to a study conducted by researchers at the University at Buffalo's Research Institute on Addictions (RIA).
Ben-Gurion University of the Negev students have developed an innovative optical radar system that helps blind people maneuver around obstacles. The radar system incorporates a computer, two video cameras and a scanning light source to warn the blind of obstacles with audible alerts. The system detects obstacles - even those overhead - by scanning the depth of its surroundings, taken from two different angles - similar to that of the human eye.
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
› Verified 6 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
Clinical Foundations, a patient-focused education program dedicated to helping respiratory care professionals stay current on clinical trends, has recently published a new edition titled "Pathogens Associated with the Intensive Care Unit Environment –Considerations for the Respiratory Therapist."
Gambling activity is widespread among U.S. adolescents and young adults ages 14 through 21, according to a study conducted by researchers at the University at Buffalo's Research Institute on Addictions (RIA).
Ben-Gurion University of the Negev students have developed an innovative optical radar system that helps blind people maneuver around obstacles. The radar system incorporates a computer, two video cameras and a scanning light source to warn the blind of obstacles with audible alerts. The system detects obstacles - even those overhead - by scanning the depth of its surroundings, taken from two different angles - similar to that of the human eye.
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Boyd Damp, MD 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: (615) 322-2318 | Julie Boyd Damp, MD 1215 21st Ave S, Mce 5th Floor South Tower, Nashville, TN 37232-0014 Ph: (615) 322-2318 |
News Archive
Clinical Foundations, a patient-focused education program dedicated to helping respiratory care professionals stay current on clinical trends, has recently published a new edition titled "Pathogens Associated with the Intensive Care Unit Environment –Considerations for the Respiratory Therapist."
Gambling activity is widespread among U.S. adolescents and young adults ages 14 through 21, according to a study conducted by researchers at the University at Buffalo's Research Institute on Addictions (RIA).
Ben-Gurion University of the Negev students have developed an innovative optical radar system that helps blind people maneuver around obstacles. The radar system incorporates a computer, two video cameras and a scanning light source to warn the blind of obstacles with audible alerts. The system detects obstacles - even those overhead - by scanning the depth of its surroundings, taken from two different angles - similar to that of the human eye.
A Ludwig Cancer Research study shows that an experimental drug currently in clinical trials can reverse the effects of troublesome cells that prevent the body's immune system from attacking tumors.
Affymax, Inc. today reported financial results for the second quarter ended June 30, 2010. Net income for the second quarter of 2010 was $17.3 million compared to a net loss of $22.1 million for the second quarter of 2009. The company received milestone payments of $30.0 million from Takeda Pharmaceutical Company Limited for database lock of the Hematide/peginesatide Phase 3 clinical trials.
› Verified 6 days ago
Megan Desai, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |